The update of the 4th edition of the World Health Organization Classification of
Haematopoietic and Lymphatic Tissues portends important new findings and concepts in the …

Precision medicine is modernizing strategies for clinical study design to help improve
diagnoses guiding individualized treatment based on genetic or phenotypic characteristics …

The tumor cells in diffuse large B‐cell lymphomas (DLBCL) are considered to originate from
germinal center derived B‐cells (GCB) or activated B‐cells (ABC). Gene expression profiling …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-
of-origin (COO) classification of DLBCL is required in routine practice by the World Health …

Primary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) is a subtype
of DLBCL with an unfavorable prognosis and a poor response to the treatment. As we know …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with considerable
heterogeneity reflected in the 2008 World Health Organization classification. In recent years …

Diagnostics and supportive care for patients with non-Hodgkin lymphoma (NHL) in lower-
and middle-income countries (LMICs) are lacking. We hypothesized that high-throughput …

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
and demonstrates significant clinicopathologic and genetic heterogeneity. In 2000, Alizadeh …

Fine needle samples of lymph nodes and extranodal lymphoid tissues are common in
cytopathology practice. Diagnosis and classification of hematolymphoid disorders has been …

In 2017, it is estimated that 80 000 new patients will be diagnosed with non-Hodgkin
lymphoma (NHL) in the United States. 1 The NHLs are classified into more than 60 …